Search This Blog

Thursday, November 12, 2026

Assembly: Gilead's $75M extension fee extends cash runway into 2029

 

Assembly Biosciences reports fiscal Q3 2026 net loss of $20.3M, with Gilead's $75M extension fee extending cash runway into 2029

  • Fiscal Q3 2026 revenue was $3.0M, down 73% YoY and below estimates
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)